Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rodvold Keith A.¹^ORCID,Bader Justin²,Bruss Jon B.²,Hamed Kamal²^ORCID

Affiliation:

1. University of Illinois Chicago, Chicago, Illinois, USA

2. Spero Therapeutics, Inc., Cambridge, Massachusetts, USA

Abstract

SPR206 is a next-generation polymyxin being developed for the treatment of multidrug-resistant (MDR) Gram-negative infections. This Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206’s safety and pharmacokinetics in plasma, pulmonary epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy volunteers.

Funder

Spero Therapeutics, Inc

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00426-23

Reference64 articles.

1. World Health Organization. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 22 May 2023.

2. Antibiotic resistance threats in the United States, 2019

3. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

4. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features

5. Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012–2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects;Antimicrobial Agents and Chemotherapy;2024-04-22

2. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials;Expert Opinion on Investigational Drugs;2024-03-06

3. Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment;Antimicrobial Agents and Chemotherapy;2023-11-15